Kolltan Pharmaceuticals rakes in $60 mln
Kolltan Pharmaceuticals said Wednesday that it has secured $60 million in Series D financing. The investors included KLP Enterprises, Deerfield Management, HBM Healthcare Investments Ltd., Purdue Pharma and Osage University Partners. Based in New Haven, Conn., Kolltan Pharmaceuticals is a biopharmaceutical company that targets receptor tyrosine kinases.
26 March 2014•3 mins read
